Resistens mot acetylsalicylsyra - klinisk diagnos utan klarlagd mekanism
(2004) In Läkartidningen 101(45). p.3504-3509- Abstract
- A review on the subject of aspirin resistance and its role in vascular diseases is presented. Although the clinical diagnosis of aspirin resistance is frequently made, little is known about its biochemical background. Only a few follow-up studies, with varying design, have dealt with the possible association between an aspirin resistant phenotype and clinical outcome in patients with atherothrombosis. However, it was recently shown that ibuprofen acts as a competitive inhibitor in the blockage of COX-1. This pharmacodynamic interaction results in secondary aspirin resistance, which may have clinical significance in patients taking both medicines. With the complex nature of vascular diseases in mind, it is not surprising that aspirin used... (More)
- A review on the subject of aspirin resistance and its role in vascular diseases is presented. Although the clinical diagnosis of aspirin resistance is frequently made, little is known about its biochemical background. Only a few follow-up studies, with varying design, have dealt with the possible association between an aspirin resistant phenotype and clinical outcome in patients with atherothrombosis. However, it was recently shown that ibuprofen acts as a competitive inhibitor in the blockage of COX-1. This pharmacodynamic interaction results in secondary aspirin resistance, which may have clinical significance in patients taking both medicines. With the complex nature of vascular diseases in mind, it is not surprising that aspirin used as a single preventive strategy fails in many cases. At present, there is no clear evidence that treatment failure is associated with a particular aspirin resistant phenotype. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/132192
- author
- Hillarp, Andreas LU
- organization
- alternative title
- Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Platelet Aggregation Inhibitors: metabolism, Platelet Aggregation: drug effects, Ibuprofen: metabolism, Ibuprofen: pharmacology, Humans, Phenotype, Fibrinolytic Agents: pharmacology, Fibrinolytic Agents: metabolism, English Abstract, Drug Tolerance: genetics, Drug Resistance: genetics, Drug Interactions, Cyclooxygenase Inhibitors: pharmacology, Cyclooxygenase Inhibitors: metabolism, Cardiovascular Diseases: metabolism, Cardiovascular Diseases: drug therapy, Bleeding Time, Aspirin: metabolism, Aspirin: pharmacology, Platelet Aggregation Inhibitors: pharmacology
- in
- Läkartidningen
- volume
- 101
- issue
- 45
- pages
- 3504 - 3509
- publisher
- Swedish Medical Association
- external identifiers
-
- scopus:8844255583
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- id
- c94b2ddf-edd4-4046-a8cd-161d5151674b (old id 132192)
- alternative location
- http://ltarkiv.lakartidningen.se/artNo29369
- date added to LUP
- 2016-04-01 15:37:22
- date last changed
- 2022-01-28 06:16:32
@article{c94b2ddf-edd4-4046-a8cd-161d5151674b,
abstract = {{A review on the subject of aspirin resistance and its role in vascular diseases is presented. Although the clinical diagnosis of aspirin resistance is frequently made, little is known about its biochemical background. Only a few follow-up studies, with varying design, have dealt with the possible association between an aspirin resistant phenotype and clinical outcome in patients with atherothrombosis. However, it was recently shown that ibuprofen acts as a competitive inhibitor in the blockage of COX-1. This pharmacodynamic interaction results in secondary aspirin resistance, which may have clinical significance in patients taking both medicines. With the complex nature of vascular diseases in mind, it is not surprising that aspirin used as a single preventive strategy fails in many cases. At present, there is no clear evidence that treatment failure is associated with a particular aspirin resistant phenotype.}},
author = {{Hillarp, Andreas}},
issn = {{0023-7205}},
keywords = {{Platelet Aggregation Inhibitors: metabolism; Platelet Aggregation: drug effects; Ibuprofen: metabolism; Ibuprofen: pharmacology; Humans; Phenotype; Fibrinolytic Agents: pharmacology; Fibrinolytic Agents: metabolism; English Abstract; Drug Tolerance: genetics; Drug Resistance: genetics; Drug Interactions; Cyclooxygenase Inhibitors: pharmacology; Cyclooxygenase Inhibitors: metabolism; Cardiovascular Diseases: metabolism; Cardiovascular Diseases: drug therapy; Bleeding Time; Aspirin: metabolism; Aspirin: pharmacology; Platelet Aggregation Inhibitors: pharmacology}},
language = {{swe}},
number = {{45}},
pages = {{3504--3509}},
publisher = {{Swedish Medical Association}},
series = {{Läkartidningen}},
title = {{Resistens mot acetylsalicylsyra - klinisk diagnos utan klarlagd mekanism}},
url = {{http://ltarkiv.lakartidningen.se/artNo29369}},
volume = {{101}},
year = {{2004}},
}